{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:14:35Z","timestamp":1792793675427,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["CM48 and CM444"],"award-info":[{"award-number":["CM48 and CM444"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7224\/A23275"],"award-info":[{"award-number":["C7224\/A23275"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51236-6","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:43:56Z","timestamp":1723506236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-5733","authenticated-orcid":false,"given":"Emmanuel C.","family":"Patin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-3179","authenticated-orcid":false,"given":"Pablo","family":"Nenclares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-5699","authenticated-orcid":false,"given":"Charleen","family":"Chan Wah Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-5227","authenticated-orcid":false,"given":"Magnus T.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Patrikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-7404","authenticated-orcid":false,"given":"Shane","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6179-391X","authenticated-orcid":false,"given":"Joao P.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Baldock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Gkantalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Roulstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Kyula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3074-6439","authenticated-orcid":false,"given":"Amy","family":"Burley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-3016","authenticated-orcid":false,"given":"Simon A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Clancy-Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-3380","authenticated-orcid":false,"given":"Alan A.","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-7326","authenticated-orcid":false,"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7365-9629","authenticated-orcid":false,"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"51236_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"51236_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156\u2013167 (2019).","journal-title":"Lancet"},{"key":"51236_CR3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/annonc\/mdw428","volume":"27","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Ann. Oncol. 27, 2257\u20132262 (2016).","journal-title":"Ann. Oncol."},{"key":"51236_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","volume":"22","author":"NY Lee","year":"2021","unstructured":"Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450\u2013462 (2021).","journal-title":"Lancet Oncol."},{"key":"51236_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","volume":"34","author":"Y Tao","year":"2023","unstructured":"Tao, Y. et al. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 34, 101\u2013110 (2023).","journal-title":"Ann Oncol."},{"key":"51236_CR6","doi-asserted-by":"publisher","first-page":"960852","DOI":"10.3389\/fimmu.2022.960852","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang, X., Xiong, H. & Ning, Z. Implications of NKG2A in immunity and immune-mediated diseases. Front. Immunol. 13, 960852 (2022).","journal-title":"Front. Immunol."},{"key":"51236_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre, P. et al. Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e1713 (2018).","journal-title":"Cell"},{"key":"51236_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N van Montfoort","year":"2018","unstructured":"van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744\u20131755 e1715 (2018).","journal-title":"Cell"},{"key":"51236_CR9","doi-asserted-by":"crossref","unstructured":"Segal, N. H. et al. First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer. J. Clin. Oncol. 36 (2018).","DOI":"10.1200\/JCO.2018.36.15_suppl.3540"},{"key":"51236_CR10","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"51236_CR11","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase 2 NeoCOAST platform trial. Cancer Discov. 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov."},{"key":"51236_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2021.09.003","volume":"158","author":"R Galot","year":"2021","unstructured":"Galot, R. et al. A phase II study of monalizumab in patients with recurrent\/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur. J. Cancer 158, 17\u201326 (2021).","journal-title":"Eur. J. Cancer"},{"key":"51236_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/mc.23384","volume":"61","author":"P Karukonda","year":"2022","unstructured":"Karukonda, P., Odhiambo, D. & Mowery, Y. M. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Mol. Carcinog. 61, 225\u2013238 (2022).","journal-title":"Mol. Carcinog."},{"key":"51236_CR14","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon, M. T. et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin. Cancer Res. 25, 3392\u20133403 (2019).","journal-title":"Clin. Cancer Res."},{"key":"51236_CR15","doi-asserted-by":"publisher","first-page":"e004306","DOI":"10.1136\/jitc-2021-004306","volume":"10","author":"EC Patin","year":"2022","unstructured":"Patin, E. C. et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J. Immunother. Cancer 10, e004306 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"51236_CR16","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti, F. P. et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J. Clin. Invest. 128, 3926\u20133940 (2018).","journal-title":"J. Clin. Invest."},{"key":"51236_CR17","doi-asserted-by":"publisher","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother. Cancer 8, e000340 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"51236_CR18","doi-asserted-by":"publisher","first-page":"e165615","DOI":"10.1172\/jci.insight.165615","volume":"8","author":"FP Vendetti","year":"2023","unstructured":"Vendetti, F. P. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8, e165615 (2023).","journal-title":"JCI Insight"},{"key":"51236_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27619-4","volume":"12","author":"CHL Kurten","year":"2021","unstructured":"Kurten, C. H. L. et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat. Commun. 12, 7338 (2021).","journal-title":"Nat. Commun."},{"key":"51236_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","volume":"52","author":"AR Cillo","year":"2020","unstructured":"Cillo, A. R. et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity 52, 183\u2013199 e189 (2020).","journal-title":"Immunity"},{"key":"51236_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/0008-5472.CAN-11-1831","volume":"72","author":"NP Judd","year":"2012","unstructured":"Judd, N. P. et al. ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72, 365\u2013374 (2012).","journal-title":"Cancer Res."},{"key":"51236_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/hed.21040","volume":"31","author":"R Williams","year":"2009","unstructured":"Williams, R. et al. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31, 911\u2013918 (2009).","journal-title":"Head Neck"},{"key":"51236_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/archotol.133.5.495","volume":"133","author":"AC Hoover","year":"2007","unstructured":"Hoover, A. C. et al. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch. Otolaryngol. Head Neck Surg. 133, 495\u2013502 (2007).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"51236_CR24","doi-asserted-by":"publisher","first-page":"e99013","DOI":"10.15252\/embj.201899013","volume":"37","author":"D Bending","year":"2018","unstructured":"Bending, D. et al. A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme. EMBO J. 37, e99013 (2018).","journal-title":"EMBO J."},{"key":"51236_CR25","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1083\/jcb.201711048","volume":"217","author":"D Bending","year":"2018","unstructured":"Bending, D. et al. A timer for analyzing temporally dynamic changes in transcription during differentiation in vivo. J. Cell Biol. 217, 2931\u20132950 (2018).","journal-title":"J. Cell Biol."},{"key":"51236_CR26","doi-asserted-by":"publisher","unstructured":"Hassan, J. et al. Single-cell level temporal profiling of tumour-reactive T cells under immune checkpoint blockade. bioRxiv https:\/\/doi.org\/10.1101\/2022.07.19.500582 (2022).","DOI":"10.1101\/2022.07.19.500582"},{"key":"51236_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki, N. K. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 22, 824\u2013835 (2021).","journal-title":"Lancet Oncol."},{"key":"51236_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"51236_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"51236_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JCO.20.00290","volume":"39","author":"S McBride","year":"2021","unstructured":"McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol 39, 30\u201337 (2021).","journal-title":"J Clin Oncol"},{"key":"51236_CR31","unstructured":"Salome, B. et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 40, 1027\u20131043 e1029 (2022)."},{"key":"51236_CR32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ijc.33859","volume":"150","author":"L Borst","year":"2022","unstructured":"Borst, L. et al. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. Int. J. Cancer 150, 688\u2013704 (2022).","journal-title":"Int. J. Cancer"},{"key":"51236_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.4049\/jimmunol.2100044","volume":"209","author":"NG Battaglia","year":"2022","unstructured":"Battaglia, N. G. et al. Combination of NKG2A and PD-1 blockade improves radiotherapy response in radioresistant tumors. J. Immunol. 209, 629\u2013640 (2022).","journal-title":"J. Immunol."},{"key":"51236_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2015.135301","volume":"101","author":"L Ruggeri","year":"2016","unstructured":"Ruggeri, L. et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica 101, 626\u2013633 (2016).","journal-title":"Haematologica"},{"key":"51236_CR35","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J. Clin. Invest. 129, 2094\u20132106 (2019).","journal-title":"J. Clin. Invest."},{"key":"51236_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","volume":"74","author":"L Poncette","year":"2022","unstructured":"Poncette, L., Bluhm, J. & Blankenstein, T. The role of CD4 T cells in rejection of solid tumors. Curr. Opin. Immunol. 74, 18\u201324 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"51236_CR37","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","volume":"70","author":"R Bos","year":"2010","unstructured":"Bos, R. & Sherman, L. A. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70, 8368\u20138377 (2010).","journal-title":"Cancer Res."},{"key":"51236_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/2326-6066.CIR-16-0293","volume":"5","author":"A Arina","year":"2017","unstructured":"Arina, A. et al. Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1-resistant tumors leading to tumor eradication. Cancer Immunol. Res. 5, 127\u2013136 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"51236_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2326-6066.CIR-17-0134","volume":"6","author":"NP Rudqvist","year":"2018","unstructured":"Rudqvist, N. P. et al. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol. Res. 6, 139\u2013150 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"51236_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992630","volume":"13","author":"J John","year":"2022","unstructured":"John, J. et al. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Front. Immunol. 13, 992630 (2022).","journal-title":"Front. Immunol."},{"key":"51236_CR41","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","volume":"39","author":"L Au","year":"2021","unstructured":"Au, L. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497\u20131518 e1411 (2021).","journal-title":"Cancer Cell"},{"key":"51236_CR42","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845\u20131851 (2018).","journal-title":"Nat. Med."},{"key":"51236_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24343-x","volume":"12","author":"S Valpione","year":"2021","unstructured":"Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).","journal-title":"Nat. Commun."},{"key":"51236_CR44","doi-asserted-by":"publisher","first-page":"e004512","DOI":"10.1136\/jitc-2022-004512","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J. Immunother. Cancer 10, e004512 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"51236_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TNJ Bullock","year":"2022","unstructured":"Bullock, T. N. J. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol. Immunol. 19, 14\u201322 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"51236_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10650-7","volume":"23","author":"KM Bates","year":"2023","unstructured":"Bates, K. M. et al. Spatial characterization and quantification of CD40 expression across cancer types. BMC Cancer 23, 220 (2023).","journal-title":"BMC Cancer"},{"key":"51236_CR47","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fimmu.2018.01019","volume":"9","author":"A Fahnrich","year":"2018","unstructured":"Fahnrich, A. et al. CD154 costimulation shifts the local T-cell receptor repertoire not only during thymic selection but also during peripheral T-dependent humoral immune responses. Front Immunol 9, 1019 (2018).","journal-title":"Front Immunol"},{"key":"51236_CR48","doi-asserted-by":"publisher","first-page":"e004410","DOI":"10.1136\/jitc-2021-004410","volume":"10","author":"G Bozhanova","year":"2022","unstructured":"Bozhanova, G. et al. CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. J. Immunother. Cancer 10, e004410 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"51236_CR49","doi-asserted-by":"publisher","first-page":"e1004503","DOI":"10.1371\/journal.pcbi.1004503","volume":"11","author":"M Shugay","year":"2015","unstructured":"Shugay, M. et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput. Biol. 11, e1004503 (2015).","journal-title":"PLoS Comput. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51236-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T03:03:07Z","timestamp":1723777387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51236"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51236-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. and S.A.S. are employees and stockholders of AstraZeneca. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6923"}}